We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Pharmaceuticals group Adcock Ingram’s share price rose as much as 6.3% to R69.12 on Monday morning after issuing a statement saying how much of the government’s antiretroviral medicine contract it had won. Adcock Ingram said it will supply 12% of the antiretroviral drugs state hospitals will purchase over the next three years, equating to R1.8bn excluding VAT.

“Our investment into the oral solid dosage facility situated in Wadeville has increased our ability to manufacture and supply antiretroviral medicines to the public sector through the tender system, and also meet the needs of the private healthcare market,” Adcock Ingram prescription division MD Ashley Pearce said in a media release. The local medicine manufacturer said it submitted bids for two triple combination products — Tenofovir, Emtricitabine, Efavirenz (TEE), and Dolutegravir, Lamivudine, Tenofovir (DLT) — as well as a number of the dual- and monotherapy molecules. Its share of the antiretroviral tender award ove...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now